Page 53 - Exact Sciences News Today

Exact Sciences (NASDAQ:EXAS – Get Rating) had its price objective boosted by Bank of America from $80.00 to $88.00 in a report issued on Wednesday morning, The Fly reports. Other analysts have also recently issued research reports about the company. BTIG Research cut their target price on Exact Sciences from $85.00 to $80.00 and set […]

Craig Hallum upgraded shares of Exact Sciences (NASDAQ:EXAS – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, The Fly reports. They currently have $85.00 target price on the medical research company’s stock, up from their prior target price of $55.00. Other analysts have […]

Exact Sciences Co. (NASDAQ:EXAS – Get Rating) General Counsel James Herriott sold 1,300 shares of Exact Sciences stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $79.85, for a total transaction of $103,805.00. Following the completion of the sale, the general counsel now directly owns 8,564 shares […]

Skandinaviska Enskilda Banken AB publ increased its stake in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,289 shares of the medical research company’s stock after acquiring an additional 358 shares […]

HighTower Advisors LLC cut its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 62.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 532,632 shares of the medical research company’s stock after selling 904,048 shares during the period. […]

Exact Sciences Co. (NASDAQ:EXAS – Get Rating) – SVB Leerink boosted their Q2 2023 EPS estimates for shares of Exact Sciences in a report released on Wednesday, May 10th. SVB Leerink analyst P. Souda now expects that the medical research company will post earnings of ($0.51) per share for the quarter, up from their prior […]

Exact Sciences Co. (NASDAQ:EXAS – Get Rating) General Counsel James Herriott sold 1,300 shares of the firm’s stock in a transaction that occurred on Wednesday, May 10th. The shares were sold at an average price of $79.85, for a total value of $103,805.00. Following the transaction, the general counsel now directly owns 8,564 shares of […]

Exact Sciences (NASDAQ:EXAS – Get Rating) issued its quarterly earnings results on Tuesday. The medical research company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.37, Briefing.com reports. Exact Sciences had a negative net margin of 29.92% and a negative return on equity of 19.76%. The company had […]

Lincoln National Corp bought a new position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) in the fourth quarter, Holdings Channel reports. The institutional investor bought 5,359 shares of the medical research company’s stock, valued at approximately $265,000. A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group […]

Swiss National Bank reduced its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 5.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 719,180 shares of the medical research company’s stock after selling 43,237 shares during the period. Swiss National Bank owned […]